Boston Scientific (BSX) closed at $44.38 on Oct 16, 2026, up 0.6% on the day. The stock is up 1.9% over the past month, up 1.4% over three months, down 53.5% year to date and down 54.6% over the past year. It trades 58.0% below its 52-week high of $105.65 and 7.2% above its 52-week low of $41.39. The close sits below its 50-day moving average ($46.09) and below its 200-day moving average ($59.10).
NextPick tracks BSX in its Medical Devices basket alongside ABT, ISRG, MDT, SYK and BDX. As of Oct 16, 2026, the basket's money-flow score is 15 (weak inflow), and the basket is up 4.5% over five sessions. Over the past month BSX ranks 9th of 13 basket members by price change.
BSX is scheduled to report earnings on Oct 28, 2026, before market open. Over its last 8 reports the stock moved an average of 5.1% on the first trading day after earnings, beating the options-implied move in 3 of 8.
Form 4 filings over the last 90 days show 6 open-market purchases and no open-market sales by insiders.
Boston Scientific is scheduled to report on Oct 28, 2026, before market open.
Over the last 8 reports, BSX moved an average of 5.1% on the first trading day after earnings. The move beat the options-implied move in 3 of 8 reports.
No — the Oct 16, 2026 close of $44.38 is 24.9% below the 200-day average of $59.10.
BSX closed 58.0% below its 52-week high of $105.65.
NextPick groups BSX with ABT, ISRG, MDT, SYK and BDX in its Medical Devices basket.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
